- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Stemtech Corp - 10-K, Annual Report | 1 | SEC Filings | ||
| 02.06. | Full Alliance Group, Inc.: Full Alliance Group's Pure Solutions Announces Manufacturing Agreement With Stemtech Corporation for New StemPets Product Line | 217 | ACCESS Newswire | TAMPA, FL / ACCESS Newswire / June 2, 2025 / Pure Solutions Inc., a wholly owned subsidiary of Full Alliance Group, Inc. (OTC:FAGI), today announced a strategic manufacturing agreement with Stemtech... ► Artikel lesen | |
| 02.06. | Stemtech Corporation Announces Dr. Lizette Leos' "Well-Aging" Video Series | 137 | ACCESS Newswire | NAPLES, FL / ACCESS Newswire / June 2, 2025 / Stemtech Corporation (OTCQB:STEK) is pleased to announce the "Well-Aging" video series, hosted by Dr. Lizette Leos, MD. The series presents short segments... ► Artikel lesen | |
| 28.05. | Stemtech Corporation: Stemtech Launches "StemPets" - the All-Natural Longevity Nutraceuticals Developed for Pets | 469 | ACCESS Newswire | Now Available for purchase in the U.S. Starting June 2025; Launching in Mexico Two Weeks Later NAPLES, FL / ACCESS Newswire / May 28, 2025 / Stemtech Corporation (OTCQB:STEK), the global leader in Human... ► Artikel lesen | |
| 14.04. | Stemtech Corp - 8-K, Current Report | 1 | SEC Filings | ||
| STEMTECH Aktie jetzt für 0€ handeln | |||||
| 31.03. | Stemtech Corp - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 1 | SEC Filings | ||
| 10.03. | Stemtech Corporation Announces Strategic Leadership Additions and Milestones Toward StemPets Launch in 2025 | 219 | ACCESS Newswire | NAPLES, FL / ACCESS Newswire / March 10, 2025 / Stemtech, the global leader in stem cell nutrition, is proud to announce key strategic appointments and a forward-looking path toward the launch of its... ► Artikel lesen | |
| 18.02. | Stemtech Corporation: Leading The Global Wellness - Anti-Aging Healthy Revolution | 344 | ACCESS Newswire | NAPLES, FL / ACCESS Newswire / February 18, 2025 / Stemtech Corporation (OTCQB:STEK) is redefining the future of health with its groundbreaking, all-natural, plant-based nutritional stemceuticals. Stemtech... ► Artikel lesen | |
| 05.12.24 | Stemtech Corporation / Viago and Eevia Health Announce Proposed RTO | 505 | ACCESS Newswire | NAPLES, FL / ACCESSWIRE / December 5, 2024 / Stemtech Corporation (OTCQB:STEK), a US-based company announced this past Tuesday its planned merger ("Merger") with Seacret Direct, LLC ("VIÁGO") and now... ► Artikel lesen | |
| 04.12.24 | Stemtech Corporation and Seacret Direct / Viago Execute Merger Agreement | 223 | ACCESS Newswire | NAPLES, FL / ACCESSWIRE / December 4, 2024 / Stemtech Corporation (OTCQB:STEK) is pleased to announce the merger agreement with Seacret Direct / VIÁGO, progressing their plan to establish a global leadership... ► Artikel lesen | |
| 20.11.24 | Stemtech Corporation and Viago Announce Strategic Merger | 483 | ACCESS Newswire | NAPLES, FL / ACCESSWIRE / November 20, 2024 / Stemtech Corporation (OTCQB:STEK) and Seacret Direct, LLC (doing business as VIÁGO) are pleased to announce they have reached an agreement in principle... ► Artikel lesen | |
| 26.09.24 | Stemtech Corporation: Stemtech Sets Strategic Directions and Expands Into $303 Billion Pet Health Market, Boosted by Increased Demand For Anti-Aging Innovations | 448 | ACCESS Newswire | NAPLES, FL / ACCESSWIRE / September 26, 2024 / STEMTECH CORPORATION, ("STEK") Stemtech Corporation, a pioneer in the health and wellness industry specializing in stem cell nutrition, is excited to announce... ► Artikel lesen | |
| 04.09.24 | Stemtech Corporation Announces Uplist to OTCQB, Maintains Focus on Expansion and Transparency | 431 | ACCESS Newswire | NAPLES, FL / ACCESSWIRE / September 4, 2024 / ("STEK") Stemtech Corporation, the pioneer and trailblazer in the stem cell nutrition sector, is proud to announce that OTC Markets has approved us to quote... ► Artikel lesen | |
| 22.08.24 | Stemtech Corporation: Stemtech Expands Into The $303 Billion Pet Health Care Market With Launch Of Stempets | 283 | ACCESS Newswire | NAPLES, FL / ACCESSWIRE / August 22, 2024 / Stemtech Corporation (OTCQB;STEK), a leader in the development and distribution of stemceutical products for humans offered since 2005, is proud to announce... ► Artikel lesen | |
| 18.07.24 | STEMTECH CORPORATION Update to Shareholders & Independent Business Partners | 380 | ACCESS Newswire | NAPLES, FL / ACCESSWIRE / July 18, 2024 / STEMTECH CORPORATION, (OTC Pink:STEK)As CEO of the Company, I want to publicly address the recent issues which delayed our annual "10K" and "10Q" filings with... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 26,355 | -0,40 % | Leichte Zugewinne bei der Bayer-Aktie (26,425 €) | Am deutschen Aktienmarkt notiert die Aktie von Bayer zur Stunde fester. Das Papier kostete zuletzt 26,43 Euro. Das Wertpapier von Bayer verzeichnet gegenwärtig ein Kursplus von 0,06 Prozent. Es hat... ► Artikel lesen | |
| MERCK KGAA | 112,70 | +0,27 % | UBS stuft MERCK KGAA auf 'Buy' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Merck KGaA mit Blick auf das dritte Quartal 2025 auf "Buy" belassen. In den Fokus könnten Nachrichten zum Medikament Varegacestat... ► Artikel lesen | |
| GSK | 16,420 | -0,82 % | JPMORGAN stuft GSK auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat GSK den Stempel "Negative Catalyst Watch" aufgedrückt. Das Risiko eines negativen Votums der US-Gesundheitsbehörde FDA für das Medikament Blenrep... ► Artikel lesen | |
| EYENOVIA | 15,840 | 0,00 % | Eyenovia, Inc.: Eyenovia Announces Rebranding and Corporate Name Change to Hyperion DeFi, Inc. | Name change reflects company's leadership position with its cryptocurrency treasury reserve strategy focused on the HYPE token Company to commence trading on Nasdaq under the symbol "HYPD" effective... ► Artikel lesen | |
| SCHOTT PHARMA | 26,600 | -1,12 % | Schott Pharma-Aktie leicht im Plus (28,50 €) | An der deutschen Börse liegt die Schott Pharma-Aktie zur Stunde im Plus. Der jüngste Kurs betrug 28,50 Euro. Die Schott Pharma-Aktie verzeichnet aktuell ein Kursplus von 1,42 Prozent. Sie hat sich um... ► Artikel lesen | |
| ELI LILLY | 659,70 | -1,26 % | Eli Lilly | Rolls-Royce | VW - Rücksetzer bei Palantir ausnutzen? | Markus Weingran - Mein Tipp: SMARTBROKER+: https://dwbdiv.smartbrokerplus.de/ts/94450/tsc - typ=r&amc=con.smartbrokerplus.536232.548190.CRTuFopWREk&smc1=YouTube (Werbung) Willkommen bei der Börsenlounge... ► Artikel lesen | |
| ASTRAZENECA | 120,70 | -0,66 % | BERNSTEIN RESEARCH stuft ASTRAZENECA auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat die Einstufung für Astrazeneca mit einem Kursziel von 16500 Pence auf "Outperform" belassen. Justin Smith zeigt sich in einer... ► Artikel lesen | |
| DERMAPHARM | 35,000 | -0,28 % | EQS-News: Dermapharm Holding SE: Hauptversammlung beschließt Dividendenausschüttung in Höhe von 0,90 € je Aktie | EQS-News: Dermapharm Holding SE
/ Schlagwort(e): Hauptversammlung/Dividende
Dermapharm Holding SE: Hauptversammlung beschließt Dividendenausschüttung in Höhe von 0,90 € je Aktie... ► Artikel lesen | |
| ABBVIE | 161,60 | -0,12 % | AbbVie: 2,1 Milliarden US$ für privaten CAR-T-Entwickler | Der US-Pharmariese AbbVie gibt heute die Übernahme des privat gehaltenen Zelltherapie-Entwicklers Capstan Therapeutics bekannt. Den Deal lässt sich der Konzern satte 2,1 Milliarden US$ kosten. Mit der... ► Artikel lesen | |
| ROCHE | 279,80 | +0,18 % | Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen | ||
| UCB | 166,90 | 0,00 % | UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder | Phase 3 study met primary and most key secondary clinical endpoints
This marks the third developmental and epileptic encephalopathies (DEE) population for fenfluramine... ► Artikel lesen | |
| METSERA | 28,860 | 0,00 % | Metsera, Inc.: Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i | Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination Well-tolerated... ► Artikel lesen | |
| HARROW | 30,580 | 0,00 % | Formosa Pharmaceuticals Inc.: Harrow Health, Inc. Acquires U.S. Commercial Rights to BYQLOVI (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals | TAIPEI, June 9, 2025 /PRNewswire/ -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan -based Formosa Pharmaceuticals... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 3,655 | +7,50 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | Submitted NDA for Anaphylm (epinephrine), the first and only oral sublingual film for patients with severe allergic reactions Advancing commercial readiness efforts with a planned Q1 2026 launch of... ► Artikel lesen | |
| VYNE THERAPEUTICS | 1,510 | 0,00 % | VYNE Therapeutics Inc.: VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202 |
STEMTECH CORPORATION gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu STEMTECH CORPORATION finden Sie auf Wallstreet Online.